Background/Aims: Elevated pretreatment plasma D-dimer level has been reported as an unfavorable prognostic indicator in several malignancies. The aim of this meta-analysis was to evaluate the prognostic value of elevated D-dimer level in solid tumors. Methods: A comprehensive search of electronic databases up to June 10, 2017 was carried out by two independent reviewers. We included studies exploring the association between pretreatment plasma D-dimer level and patients' survival outcomes in solid tumors. Overall survival (OS) was regarded as primary outcome and progression-free survival (PFS), disease-free survival (DFS) as well as cancer-specific survival (CSS) were chosen as secondary outcomes. Hazard ratio and 95% confidence interval (CI) were extracted directly or indirectly from included studies. Results: 49 studies with 13001 patients were included in our meta-analysis. Elevated D-dimer was markedly associated with poor OS (pooled HR = 1.90, 95% CI = 1.63 -2.20, P < 0.001). The effect was observed in all different tumor sites, disease stages, cut-off values and ethnicities. Meanwhile, patients with a high plasma D-dimer had a shorter PFS (HR = 1.46, 95% CI = 1.22-1.76; P < 0.001), DFS (HR = 2.02, 95% CI = 1.56-2.62) and CSS (HR = 2.04, 95% CI= 1.58 -2.64). Conclusions: Analysis of the pretreatment plasma D-dimer might provide useful information to predict prognosis in patients with solid tumors.
Introduction
The hemostatic system plays an important role in coordinating the balance between bleeding and clot formation. Interestingly, abnormal activation of coagulation and fibrinolysis is frequently present in cancer patients, especially in patients with metastatic disease [1] [2] [3] [4] [5] [6] [7] [8] [9] . The spectrum of hemostatic abnormalities ranges from massive thromboembolism to abnormal coagulation parameters in the absence of clinical symptoms [10] . This phenomenon may due to the fact that tumor cells could possess strong procoagulant activities, resulting in coagulation system's local activation and fibrin deposition [11] . The formation of plateletfibrin-tumor cell creates an extracellular microenvironment that can facilitate tumor cell growth and survival.
D-dimer, a plasmin-mediate degradation product of cross-linked fibrin, is a biomarker for routine use in clinical practice of deep venous thrombosis (DVT), disseminated intravascular coagulation (DIC) and pulmonary embolism (PE). Circulating D-dimer may also elevated in patients with coronary artery disease, trauma, pregnancy and inflammatory diseases [12, 13] . Recent articles reported that plasma D-dimer was markedly elevated in patients with different malignancies before treatment, including lung cancer [1] [2] [3] , prostate cancer [4, 5] , cervical cancer [6, 7] , breast cancer [8] and colorectal cancer [9] . However, the prognosis role of D-dimer in cancer is still controversial. Some reported that an elevated D-dimer level before treatment is associated with a more advanced tumor stage or a more advanced clinical progression therefore it may indicate a worse prognosis. While others claimed the connection was insignificant. For now, there has been no systematic attempt to explore the consistency and magnitude of its prognostic value. Thus, we conducted this systemic review and meta-analysis to elucidate the prognostic role of D-dimer in solid tumors.
Materials and Methods

Data sources
The present meta-analysis was strictly performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14] . We conducted a comprehensive review of Pubmed database up to June 10 by two independent reviewers. The key terms of this analysis include "cancer", "D-dimer" and "prognosis". Meanwhile, we searched abstracts of the American Society of Clinical Oncology (ASCO) using the same search terms. Additionally, an independent search of Embase, the web of science and Cochrane Library database was also carried out in case of missing any other information. The search results were limited to human studies published in English language.
Study selection
Studies eligible for this analysis had to meet the following criteria: (1) prospective or retrospective cohort studies of patient with non-hematologic solid tumors; (2) assessment of the prognostic effect of pretreatment D-dimer on overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) or cancer-specific survival (CSS). (3) containing sufficient data to extract or calculate the hazard ratio (HR) and its 95% confidence interval (CI). Articles were excluded if they contained any of the following criteria:
(1) articles of patient with hematologic malignancies; (2) duplicate publication; (3) animal experiments, non-English papers; (4) comments, reviews, case reports or meta-analyses containing no original data; (4) insufficient data for extracting or calculating of HR and its 95% CI.
Two independent reviewers (YC Song, H Zhang) evaluated all the selected titles and abstracts to exclude duplicated publications and apparent irrelevant studies. Then the results were pooled and full texts were retrieved to assess eligibility. Any discrepancies were resolved by consensus. Corresponding authors were contacted to clarify missing or ambiguous data. 
Quality assessment
Two independent investigators (QN Zeng, B Hou) assessed the quality of the included studies according to Study OBservational studies in Epidemiology (STROBE) recommendations with an adjustment to the specific characteristics of the study [15] . The score of each article was assessed based on whether the following criteria were clearly stated: study hypothesis, tumor stage, description of eligibility criteria, whether patients with VTE or receive anticoagulation therapy were excluded, outcome endpoints definition, confounding factors considered in multivariate analysis, follow-up period, limitations and bias. We ranked the included studies according to the criteria considered in the analysis (quality score: 0 -8). All discrepancies were discussed and resolved with consensus.
Statistical analysis
All statistical analysis was performed with the STATA software package (version 13.1) (Stata Corp LP, College Station, TX). We considered OS was the primary endpoint in this analysis and PFS, DFS and CSS were secondary outcomes. HRs with corresponding 95% CIs were directly extracted from each study if it is feasible. For studies only providing Kaplan-Meier survival curves, data were calculated by using software Engauge Digitizer Version 4.1 [16, 17] . HR values > 1 indicated a poor survival with elevated serum D-dimer while HR values < 1 implied a survival benefit with increased serum D-dimer, the result was considered statistically significant if the 95% CI did not overlap 1. The heterogeneity of data among included studies was examined using Cochran's Q-test and Higgins-I 2 statistic. We define heterogeneity was insignificant if I 2 value < 50% and we use a fixed-effect model to calculate the parameters. If I 2 value ≥ 50%, we consider there exists a significant heterogeneity and a random-effect model will be applied to the data. Subgroup analyzes were conducted according to (1) primary tumor site, (2) disease stage (non-metastatic, metastatic, mixed) (3) D-dimer cut-off value, (4) patients' ethnicity (Asian, Non-Asian), (5) study design (retrospective, prospective). Moreover, sensitivity analyzes were performed to explore the impacts on pooled effect by removing the study sequentially. Meanwhile, metaregression was performed to assess whether moderator variables could influence the pool effect size for OS. Assessment of publication bias was shown by funnel plots, confirmed by Egger's tests and Begg's test. If publication bias is significant, the Duval and Tweedie's ''Trim and Fill" method will be used to estimate a corrected effect size after adjustment [18] . Two-sided P values < 0.05 were considered statistically significant.
Results
Study characteristics
3175 publications were initially identified following our search strategy. After removing duplicated publications, 1448 studies were selected for further analysis. We next screened the titles and abstracts of each article. Reviews, case reports, in vitro studies and non-human studies were excluded in our analysis. Consequently, 114 eligible studies received full text evaluation. Among them, 65 studies with insufficient survival data were excluded from this analysis. Thus, a total of 49 studies with 12649 patients fulfilled our inclusion criteria and were enrolled in our study. The selection process is shown in Fig. 1 . Table 1 summarized the baseline characteristics of the included studies. Briefly, the publication time of included studies was between 1997 and 2017. Thirty studies collected data retrospectively while the rest used a prospective study design. D-dimer concentration was measure by either immunoturbidimetric assay (ITM) or Latex Test with various cut-off values among those studies. Of all eligible studies, Fifteen studies reported on lung cancer [2, 3, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , followed by colorectal cancer (n = 9) [9, 21, [32] [33] [34] [35] [36] [37] [38] , gastric cancer (n = 5) [21, [39] [40] [41] [42] , pancreatic cancer (n = 5) [21, [43] [44] [45] [46] , ovarian cancer (n = 3) [47] [48] [49] , esophageal cancer (n = 3) [50] [51] [52] , cervical cancer (n = 2) [6, 7] , renal cancer (n = 2) [21, 53] , sarcoma cancer (n = 2) [54, 55] , brain cancer (n = 2) [21, 56] , endometrial cancer (n = 2) [57, 58] , breast cancer (n = 1) [21] , nasopharyngeal cancer (n = 1) [59] , prostate cancer (n = 1) [21] , malignant Fig. 2 , a high pretreatment D-dimer was significantly associated with shorter OS in a randomeffects model (pooled HR = 1.90, 95% CI = 1.63 -2.20, P < 0.001) with significant heterogeneity among studies (I 2 = 75.1%, P < 0.001).
Subgroup analyses were performed according to different tumor site. As shown in Fig. 3 , We found that the highest predicting effect of elevated baseline D-dimer on OS was endometrial cancer (pooled HR = 21.7, 95% CI = 8.82 -50.36, P < 0.001), followed by cervical cancer (pooled HR = 2.23, 95% CI = 1.30 -3.82, P = 0.003) and gastric cancer (pooled HR = 1.92, 95% CI = 1.41 -2.60, P < 0.001). High heterogeneity was observed among studies Hong [37] Sun [44] Chen [25] Nakamura [6] Raj [55] Diao [39] Liu [42] Fukumoto [3] Stender [9] Zhu [35] Liu [62] Tekegin [36] Liu [43] Study Hoke [56] Tellioglu [33] Buccheri [31] Zhang [22] Diao [50] Desch [60] Guo [27] Chen [59] Sakurai [49] Luo [7] Blackwell [32] Stender [45] Liu [47] Nakamura [58] Erdem [53] Man [48] Masago [20] Li [57] Wang [2] Altiay [19] Zhu [26] Han [28] Oya [38] of colorectal cancer (I 2 = 84.3, P < 0.001), lung cancer (I 2 = 69.3, P < 0.001) and other cancer (I 2 = 62.5, P = 0.014). As for subgroup analyses by disease stage, we found there exists a significant correlation between high D-dimer value and poor overall OS in patients with non-metastatic disease (pooled HR = 1.70; 95% CI = 1.16-2.47; P = 0.006) and metastatic disease (pooled HR = 1.60; 95% CI = 1.15-2.23; P = 0.006). The HR for the mixed group including both metastatic and non-metastatic diseases was 2.10 (95% CI = 1.71-2.60; P < 0.001). There are two main detection methods (ITM and Latex test) with various cut-off values used in the studies (from 130 ng/ml to 2000 ng/ ml). Therefore, we divided those articles into different subgroups and found that patients with a high plasma D-dimer level have a worse prognosis than those with a low D-dimer level in all groups. The pooled HR > 1were consistently observed in subgroups analyses stratified by ethnicity (Non-Asian or Asian) and study design (retrospective or prospective), which provide robust evidence of plasma D-dimer levels in cancer patients could predict their prognosis regardless of ethnicity and study design (Table 3) .
Sensitivity analysis using a "one-study removed" model was conducted to testify the stability of our result. As shown in Fig. 4A , the observed effect size (pooled multivariableadjusted HR) of OS was not significantly affected by removing a single study each time. Meta-regression showed that our results were not statistically impacted by patients' ethnicity (p = 0.671), cut-off points (p = 0.217), clinical setting (p = 0.998) and study design (p = 0.967). Publication bias was found by visual inspection of the funnel plot Fig. 5D and confirmed by Begg's test and Egger's tests (all P < 0.05). However, using the ''Trim and Fill" method to adjust Erdem [53] Zhu [35] Ovarian Diao [50] Buccheri [31] Liu [43] Guo [27] Man [48] Stender [45] Nakamura [6] Hong [37] CRC Subtotal (I-squared = 0.0%, p = 0.771)
Han [28] Raj [55] Subtotal (I-squared = 84.3%, p = 0.000)
Study
Liu [47] Diao [39] Nakamura [58] Stender [9] Gastric Oya [38] Subtotal (I-squared = 0.0%, p = 0.648) Liu [42] Tekegin [36] Chen [25] Li [57] Liu [62] Subtotal (I-squared = 0.0%, p = 0.883) Subtotal (I-squared = 0.0%, p = 0.845) Luo [7] Zhu [26] Altiay [19] Subtotal (I-squared = 69.3%, p = 0.001)
Hoke [56] Wang [2] Cervical Masago [20] Subtotal (I-squared = 0.0%, p = 0.950) Tellioglu [33] Subtotal (I-squared = 62.5%, p = 0.014) Desch [60] Fukumoto [3] Pancreatic Go [40] Endometrial Sakurai [49] Blackwell [32] Chen [ Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry for publication bias, the corrected pooled effect size remained statistically significant (HR = 1.521, 95% CI = 1.305-1.774; P < 0.001 under the random-effects model). Thereby the reliability of our results could be confirmed.
A separate meta-analysis of twenty-two studies containing 5320 patients based on univariate HRs for OS showed that D-dimer level was statistically significant correlated with worse OS (pooled unadjusted HR = 1.88; 95% CI = 1.67 -2.13; P < 0.001) with high heterogeneity (I 2 = 77.8; P < 0.001) . The result was consistent with pooled multivariableadjusted HR analysis for OS.
Secondary outcome: Progression-free survival, Disease-free survival and Cancer-specific survival A total of nine studies, comprising 1231 patients, provided pooled multivariableadjusted HRs data for PFS. Overall, elevated D-dimer was significantly associated with worse PFS (HR = 1.46, 95% CI = 1.22-1.76; P < 0.001) using a fixed-effects model (I 2 = 21.6; P = 0.251) Fig. 5A . Five studies, including 2359 patients, provided data for the analysis of HRs for DFS. Of those, four studies containing 1891 patients, provided multivariable-adjusted HRs for DFS and were included in our analyses. As shown in Fig. 5B , high D-dimer level was significantly associated with poor DFS in a fixed-effects model (pooled multivariableadjusted HR = 2.02, 95% CI = 1.56-2.62; P < 0.001) with insignificant heterogeneity among studies (I 2 = 1.5%, P = 0.384). We found five articles containing data for the analysis of HRs for CSS, four of them (comprising a total of 577 patients) provided multivariable-adjusted HRs and therefore included in our analyses. As shown in Fig. 5C , the pooled HRs for CSS was 2.04 (95% CI= 1.58 -2.64; P < 0.001). Insignificant heterogeneity across studies was observed (I 2 = 32.6; P = 0.217). Sensitivity analysis was performed and we found that the observed effect size (pooled multivariable-adjusted HR) of PFS Fig. 4B and DFS Fig. 4C was not significantly influenced by removing a single study each time. However, the pooled HR for CSS increased dramatically when we removed Feng et al . [51] Fig. 4D .
Discussion
Our study provided strong evidence that an elevated pretreatment plasma D-dimer is associated with unfavorable overall survival among various cancer subgroups and across disease stages. The pooled HRs on OS was 1.90 (95% CI: 1. 63 -2.20) . By analyzing the subgroup stratified by cancer type, we found that the magnitude effect of D-dimer on OS appeared to perform its best predicted effect on cancer patient's prognosis among gynecological tumors. The highest effect was seen in endometrial cancer, followed by cervical cancer and gastric cancer. Unfavorable prognosis effect of high D-dimer remained substantial in different clinical cancer settings, different ethnicities, different detection methods with various cutoff values. The prognosis impact of a high plasma D-dimer before treatment on secondary endpoints (DFS, CSS and PFS) was consistent with OS, all pooled HRs > 1 indicating D-dimer is an unfavorable prognostic factor to cancer patients.
D-dimer is a universally available, routinely measured and simple reproducible molecular marker. Plasma D-dimer level is currently being routinely measured prior to operation. To our knowledge, this is the first article that combines all solid tumors prognostic data together to explore the prognosis value of pretreatment plasma D-dimer. The result in our analysis may be different from other meta-analyses [63] , which is partly attributed to different inclusion criteria and different research interests. Unlike other meta-analyses, we only included pretreatment D-dimer data as our analysis objects, the number of eligible studies is small but the quality and reliability of our analysis were guaranteed. Furthermore, the current cancer prognostic evaluation system has its own drawbacks that patients with the same TNM stage often have different survival outcome. D-dimer may serve as a complementary indicator that could help to improve prognosis estimation. In the current meta-analysis, we only applied HR instead of OR or RR to estimate the prognostic value, because the latter two dichotomous studies provided pooled multivariable-adjusted HR data for CSS, and the samples size of one study is larger than the total of the rest three, therefore we consider the quality of our result is not high and more studies are still needed to elucidated its clinical significance.
The mechanism of how D-dimer affect prognosis is still unknown to this day. Recent studies suggested that there exists a potential relationship between coagulation, fibrinolysis system, and tumor prognosis. Perisanidis et al. performed a meta-anlysis containing 52 studies with 15371 participants [64] . concluded that elevated pretreatment plasma fibrinogen significantly correlates with decreased survival in patients with solid tumors and came to a conclusion that fibrinogen may play a critical role in tumor progression, including epithelial-mesenchymal transition (EMT), migration, cell proliferation, angiogenesis and hematogenous metastasis [65] [66] [67] . D-dimer is known to be a degradation product of fibrin, some researchers believed D-dimer affect cancer patients' prognosis through the formation of VTE. VTE is a common complication of cancer [68, 69] . Overall, the risk of VTE in patients with cancer is as high as 7%, presumably due to the prothrombotic effect of malignant tumors and treatment-related risk factors such as immobilization, drugs, and surgical intervention [70] . However, Ay et al. [21] reported that according to their large scale prospective study data, the association of D-dimer and VTE with an unfavorable prognosis of cancer was independent of each other in solid tumors. They explained this finding with a hypothesis that abnormal elevated D-dimer may be a product of a reaction downstream from the extrinsic pathway of the coagulation cascade. Tissue factor (TF) is a key element in the initiation of the extrinsic pathway and is considered to play an important role in cancer metastasis and progression. Thus, elevated D-dimer may be a result of abnormally activated TF.
Poor prognosis of cancer patients always coincides with metastasis, a process which involves multiple tumor-host interactions. Metastatic cancer cells must leave the primary tumor, migrate into the lymphovascular system, and set up a new blood supply system. Fibrin remodeling is almost involved in all steps of metastasis and has been proven to play a crucial role in new vessel formation [74, 75] . Therefore, Blackwell et al. [76] declared that increased D-dimer levels in cancer patients may be an outcome of increased levels of fibrinolytic activity. Clinical trials about treating cancer patients with anticoagulation therapy have been carried out and reports have shown that anti-thrombotic agents, such as warfarin and low molecular weight heparin, are effective in the prevention and treatment of haematogenous metastasis as well as in the prolongation of survival [77] [78] [79] . Further studies are still needed to elucidate the biological mechanism of how high D-dimer affects the progression of malignancy as well as the treatment efficiency of anticoagulation therapy in cancer patients.
Certain limitations should be taken into consideration when interpreting study findings. Firstly, in this analysis, only 71.4% (35/49) articles excluded patients with hematologic diseases or have received anticoagulation therapy. Although most of studies involved in our meta-analysis declared that high D-dimer concentration is an independent marker for cancer prognosis, it still indicates a high risk of VTE. According to Li et al. [57] , subclinical VTE prior to surgery exists in at least 10% of patients with endometrial cancer, those undetectable VTE may put efforts on tumor prognosis. Secondly, the data we used are all extracted from published articles or directly provided by authors instead of individual participant. We also included studies provided low quality data with short duration of follow-up. Third, high heterogeneity was observed across studies since our evaluation was based on factors such as different tumor types, disease stages, measurement methods and study designs. However, if we sort these data into different subgroup analyses, a more homogeneous data was observed. Lastly, we only included studies reporting hazard ratios, therefore some studies reporting on Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the prognostic value of D-dimer were excluded (Articles only reported odds ratio for death which may introduce selection bias). Meanwhile, we only included published articles in this study, there may exist some negative result studies that were never been published. These two limitations may cause selection bias. However, the corrected pooled effect size remained statistically significant after being adjusted by "Trim and Fill" method, indicating our results could be trusted.
Conclusion
In summary, our meta-analysis provided evidence that elevated pretreatment plasma D-dimer is associated with adverse survival among patients with different types of solid tumors. Further observational and intervention studies are still needed to determine whether plasma D-dimer could be incorporated in cancer staging system. Additionally, more research should be conducted to elucidate the relationship between high D-dimer and tumor progression.
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